Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry.
about
iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancerA systematic analysis of eluted fraction of plasma post immunoaffinity depletion: implications in biomarker discoveryDistinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndromeSample preparation techniques for the untargeted LC-MS-based discovery of peptides in complex biological matricesIdentification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresisDeveloping multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometryA systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analysesAsymmetric proteome equalization of the skeletal muscle proteome using a combinatorial hexapeptide libraryEvaluating the effects of preanalytical variables on the stability of the human plasma proteomeEvaluation of a high-intensity focused ultrasound-immobilized trypsin digestion and 18O-labeling method for quantitative proteomics.Proteome profiling of human cerebrospinal fluid: exploring the potential of capillary electrophoresis with surface modified capillaries for analysis of complex biological samples.Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MSProtein extraction of formalin-fixed, paraffin-embedded tissue enables robust proteomic profiles by mass spectrometry.Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker.High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery.Establishing the proteome of normal human cerebrospinal fluidProstate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes.Proteomic technologies for the discovery of type 1 diabetes biomarkersDifferential Plasma Glycoproteome of p19 Skin Cancer Mouse Model Using the Corra Label-Free LC-MS Proteomics PlatformSampling the N-terminal proteome of human blood.Large-scale, ion-current-based proteomics investigation of bronchoalveolar lavage fluid in chronic obstructive pulmonary disease patientsCharacterization of the Human Cervical Mucous ProteomeStrategy for degradomic-peptidomic analysis of human blood plasmaOptimizing protein recovery yield from serum samples treated with beads technology.Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approachNovel Sample Preparation for Mass Spectral Analysis of Complex Biological Samples.Plasma proteome response to severe burn injury revealed by 18O-labeled "universal" reference-based quantitative proteomicsQuantitative proteomics in cardiovascular research: global and targeted strategiesDepletion of abundant plasma proteins and limitations of plasma proteomics.Combining ultracentrifugation and peptide termini group-specific immunoprecipitation for multiplex plasma protein analysis.Microscale depletion of high abundance proteins in human biofluids using IgY14 immunoaffinity resin: analysis of human plasma and cerebrospinal fluid.Protein analysis by shotgun/bottom-up proteomicsOcular proteomics with emphasis on two-dimensional gel electrophoresis and mass spectrometry.Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjectsPitfalls in protein quantitation using acid-catalyzed O18 labeling: hydrolysis-driven deamidation.The effects of eating marine- or vegetable-fed farmed trout on the human plasma proteome profiles of healthy men.Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applicationsA combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery.A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer
P2860
Q21134794-85FACB83-1481-43EE-BFAF-4B0B57FCE791Q21135230-84239DFC-DDA0-486B-AF75-BE380692C551Q21135535-EE019C37-0610-47D5-ADC7-096226F49622Q21296806-9AB6BC21-C3E9-40D4-B727-1B8D62C837F4Q24600418-3A676852-0D2B-470C-ABA2-6D47BDE9AE2BQ28395328-84A0BB27-93C5-468B-BC4A-343BE097BB65Q28732696-AC5E3804-084B-4CF5-990B-BE30AEB3621FQ28741177-56552686-AF1B-4497-B771-CB44499EFBC7Q30372676-04CDC7A4-C63D-429C-8C79-741017588744Q30480148-96730FA6-266E-442C-86FC-CEAEEA7A0E6EQ33364699-4FC4C4D5-BFB3-4A97-80C4-18EF95E55234Q33419602-B7086E1E-E373-4500-BC3E-309E410D8A03Q33453159-48255A08-B34C-4E49-8011-689A27DE9584Q33546659-7C3166B0-0F23-4165-80D6-50937B79D41BQ33579375-3959AFA4-2A82-4D58-8FFD-F75C54883296Q33605677-B2939D97-CEF8-4C2A-A508-1997E9A09BC0Q33611314-608AD1F5-7D85-4DED-BA4B-BFE8529B4B8FQ33642475-B30D00AE-3799-4A6A-9622-326405C3FAF5Q33649446-48BF761F-B642-4E84-A43C-F99111498D2DQ33740667-7938C10B-136A-4B89-B80A-0FEB00E8BC3CQ33815640-6D80EA47-8843-4E0F-9BE4-E813BF4B2D9AQ33816706-F782B16B-618F-46FE-A1EA-B7B08AB6E489Q33835867-1AAC3B6C-1CB9-4BBA-B6D5-B18D7C9563D7Q33896197-66B1088E-F39C-403C-B230-967C9878AF8CQ33946339-6DF323FE-85D8-4F6C-9EBB-A973B3EAB2A1Q33952033-B06E2C62-741B-4E60-A161-AA9A0DFAF480Q34154148-E751EA84-B1DE-4E78-A983-08BBF642195BQ34156082-6112705E-EAF8-4CD7-9461-1A88081792FCQ34168719-A21FDA10-89C1-48E5-982C-4D245663511EQ34242987-B0617CB1-A4F7-4894-B141-96561578F942Q34401658-C7FEC7B6-C348-47F7-8A2C-1D7B58BD06CBQ34600986-87EDF25D-9267-45A1-8BB2-D5F389FB565FQ34660202-978CFE12-F623-4201-8718-A05BA03F30CDQ35083863-2EAED9A1-5D9E-416E-8730-7774C12CB9B6Q35214327-24E510FB-AA9D-4D97-8379-F746450FB706Q35549463-8772CC06-F325-47A8-8F19-064194A62CD5Q35610017-868A054D-8AEC-43A8-9253-161678D52CC8Q35620650-FBE1DD95-1D05-4634-A005-A656A7810C23Q35680919-E6A6A225-9C6B-4F42-8F51-DB557D0779A1Q35736782-72E7049B-F141-49B1-9F7E-A8414CFB7A26
P2860
Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Evaluation of multiprotein imm ...... overy using mass spectrometry.
@ast
Evaluation of multiprotein imm ...... overy using mass spectrometry.
@en
type
label
Evaluation of multiprotein imm ...... overy using mass spectrometry.
@ast
Evaluation of multiprotein imm ...... overy using mass spectrometry.
@en
prefLabel
Evaluation of multiprotein imm ...... overy using mass spectrometry.
@ast
Evaluation of multiprotein imm ...... overy using mass spectrometry.
@en
P2093
P2860
P50
P1476
Evaluation of multiprotein imm ...... covery using mass spectrometry
@en
P2093
Angela D Norbeck
David G Camp
Heather M Mottaz
Marina A Gritsenko
Ronald J Moore
P2860
P304
P356
10.1074/MCP.T600039-MCP200
P577
2006-07-19T00:00:00Z